|Epigenomics AG -- USA Stock|| |
USD 5.34 0.18 3.49%
COO and Member of Executive Board
Dr. Uwe Staub resigned as Chief Operating Officer at Epigenomics AG with effect from March 31, 2018, a position he has held since April 1, 2013. Prior to that, he served as Senior Vice President Research and Development Manufacturing of the Company from November 1, 2008. He was also granted procura and will take over the responsibility for medical affairs and customer support of the Company. Before joining the Company, Dr. Staub worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development. He studied Biology at the JuliusMaximiliansUniversitaet Wuerzburg, Germany, and earned his Ph.D. degree in Biochemistry and Human Genetics.
COO Since 2013 Ph.D
49 30 243 450 http://www.epigenomics.com
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.